A feature list can tell you what a product contains without telling you whether you can finish the task you opened it for. For Anistratenco Health Assistant, we want to evaluate the first beta through a few ordinary situations rather than treating the presence of a chat box or an upload button as sufficient.
Follow a reference back to the document
Imagine using a sample report to ask what a particular term means. The intended experience is to keep the explanation connected to the relevant material, so you can distinguish what the report actually says from the assistant’s interpretation. A useful test is whether you can locate the passage being discussed without searching the entire document again.
This is an illustrative product scenario, not a patient case or a claim of clinical validation.
Keep two projects separate
Someone may be preparing questions for an appointment while also exploring a longer-term fitness goal. Grouping the conversations should make it possible to return to the right task without mixing the two into one indistinct history. We want to learn whether the workspace’s organization matches how people naturally separate those concerns.
Understand what happened when an action fails
If a document cannot be read, the experience should make that clear rather than leave you wondering whether its contents influenced the answer. Likewise, an unfinished action needs an understandable status and a sensible next step. A successful-looking screen is not enough if the person cannot tell what was actually completed.
What these scenarios mean for beta
These are criteria we are working toward, not a report that every scenario has passed or that every planned feature will be available at launch. The planned September 15, 2026 beta should give us a way to observe the gaps, explain the actual supported scope, and improve the tasks people struggle to finish.
Health Assistant’s consumer role is to help with understanding and organization; it does not turn these workflows into diagnosis, prescribing or emergency care.
Top comments (0)